Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002968 · ClinicalTrials.gov registry record · Phase 3
Edrecolomab in Treating Patients With Stage II Colon Cancer
A Phase 3 study of Mucinous Adenocarcinoma of the Colon and Signet Ring Adenocarcinoma of the Colon, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 2,100
- Enrollment target
- 1
- Study location
NCT00002968: Completed Phase 3 study of Mucinous Adenocarcinoma of the Colon and Signet Ring Adenocarcinoma of the Colon, sponsored by National Cancer Institute (NCI).
NCT00002968 is a Phase 3 study of Mucinous Adenocarcinoma of the Colon and Signet Ring Adenocarcinoma of the Colon that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,100 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (172% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002968, a Phase 3 study of Mucinous Adenocarcinoma of the Colon and Signet Ring Adenocarcinoma of the Colon, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,100 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized phase III trial to compare the effectiveness of surgery with or without monoclonal antibody therapy in treating patients who have stage II colon cancer. Monoclonal antibodies such as edrecolomab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether surgery to remove colon cancer is more effect with or without monoclonal antibody therapy.
Primary Outcome
Estimated using the Kaplan-Meier method. Compared using the logrank test.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL edrecolomab
Study Locations (1)
Illinois
- Cancer and Leukemia Group B - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,100 participants |
| Start Date | 1997-05 |
| Phase | Phase 3 |
What the finished NCT00002968 record still lists
NCT00002968 is an interventional study that assigns participants to a tested intervention. Its 2,100 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (172% higher).
The record links to 5 conditions, with Mucinous Adenocarcinoma of the Colon appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00002968 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00002968 about?
NCT00002968 is a clinical study titled "Edrecolomab in Treating Patients With Stage II Colon Cancer". Randomized phase III trial to compare the effectiveness of surgery with or without monoclonal antibody therapy in treating patients who have stage II colon cancer. Monoclonal antibodies such as edrecolomab can locate tumor cells and either kill them or deliver tumor-killing substances to them withou...
What is the current status of trial NCT00002968?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,100 participants. The study started on 1997-05.
What conditions does trial NCT00002968 study?
This clinical trial studies the following conditions: Mucinous Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Colon, Stage IIA Colon Cancer, Stage IIB Colon Cancer, Stage IIC Colon Cancer.
What interventions are being tested in trial NCT00002968?
The interventions under investigation include: laboratory biomarker analysis (OTHER), edrecolomab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002968?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002968 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucinous Adenocarcinoma of the Colon
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002968's enrollment target sits among peer trials
2,100 98th of 2000 higher than 1,902 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia